EARLY EVENTS OF INNATE IMMUNITY ARE MODIFIED BY THE NANOFORMULATION OF VACCINE COMPONENTS

CONSTANZA MARIN; FEDERICO DANIEL RUIZ MORENO; MERCEDES PASCUAL; SANTIAGO PALMA; DANIEL ALLEMANDI; GABRIEL MORÓN; MARÍA C PISTORESI- PALENCIA; BELKYS A. MALETTO

San Miguel de Tucumán

Congreso; LXVII Reunión de la Sociedad Argentina de Inmunología; 2019

Sociedad Argentina de Inmunología

Subunitvaccines are often poorly immunogenic and require a strong adjuvant. Therefore,new adjuvant strategies are demanded to develop new vaccines. We formulated OVAand CpG-ODN with a nanostructure (Coa-ASC16) formed by self-assembly of6-O-ascorbyl palmitate. This nanoformulation (OCC) elicited strong humoral andcellular (CD4+andCD8+)responses, which are superior to those induced by a solution of OVA and CpG-ODN(OC). Nonetheless, some characteristics about action mechanism of Coa-ASC16remain to be elucidated. In this work we study some aspects about early immuneevents. Mice were subcutaneously immunized with OC or OCC formulation.Cytokines/chemokines were quantified in lymph nodes and serum at 0.33, 2, 24and 48 hours post-immunization by LEGENDplex Mouse Inflammation Panel 13-plex.We further determined by flow cytometry, OVA and CpG-ODN cellular uptake inlymph nodes 24 hours post-immunization. Lymph nodes of OCC immunized miceshowed higher levels of IFN-γ, IL-12p70,IL-1β, IL-10, IL-6, IL-27,IL-17A and IFN-β than mice immunized withOC (p<0.05).In contrast, OC immunized mice display higher levels of IFN-γ, TNF-α,MCP-1,IL-12p70 and IL-6 in serum than OCC immunized mice (p<0.05). Moreover, miceimmunized with OCC showed a higher absolute number of OVA+,CpG-ODN+andOVA+CpG-ODN+ monocytes(Ly6ChighLy6GCD11b+) anddendritic cells (Ly6C-Ly6G-CD11c+)than mice immunized with OC (p<0.05). In conclusion, the nanoformulation ofvaccine components modifies the cytokines/chemokines profile and promotes theco-uptake of antigen and immunostimulant by cells that infiltrate the lymphnode. <!-- /* Font Definitions */ @font-face{font-family:Helvetica;panose-1:0 0 0 0 0 0 0 0 0 0;mso-font-alt:Helvetica;mso-font-charset:0;mso-generic-font-family:auto;mso-font-pitch:variable;mso-font-signature:-536870145 1342208091 0 0 415 0;}@font-face{font-family:"Cambria Math";panose-1:2 4 5 3 5 4 6 3 2 4;mso-font-charset:0;mso-generic-font-family:roman;mso-font-pitch:variable;mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face{font-family:Calibri;panose-1:2 15 5 2 2 2 4 3 2 4;mso-font-alt:Calibri;mso-font-charset:0;mso-generic-font-family:swiss;mso-font-pitch:variable;mso-font-signature:-536859905 -1073697537 9 0 511 0;}@font-face{font-family:"Times New Roman \(Cuerpo en alfa";panose-1:2 11 6 4 2 2 2 2 2 4;mso-font-alt:"Times New Roman";mso-font-charset:0;mso-generic-font-family:roman;mso-font-pitch:variable;mso-font-signature:-536859921 -1073711039 9 0 511 0;}@font-face{font-family:" ßU\0027E9˛";panose-1:2 11 6 4 2 2 2 2 2 4;mso-font-alt:Calibri;mso-font-charset:77;mso-generic-font-family:auto;mso-font-pitch:auto;mso-font-signature:3 0 0 0 1 0;} /* Style Definitions */ p.MsoNormal, li.MsoNormal, div.MsoNormal{mso-style-unhide:no;mso-style-qformat:yes;mso-style-parent:"";margin:0cm;margin-bottom:.0001pt;mso-pagination:widow-orphan;font-size:12.0pt;font-family:Helvetica;mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-bidi-font-family:"Times New Roman \(Cuerpo en alfa";mso-ansi-language:ES-TRAD;mso-fareast-language:EN-US;}.MsoChpDefault{mso-style-type:export-only;mso-default-props:yes;font-family:Helvetica;mso-ascii-font-family:Helvetica;mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-font-family:Helvetica;mso-bidi-font-family:"Times New Roman \(Cuerpo en alfa";mso-ansi-language:ES-TRAD;mso-fareast-language:EN-US;}size:595.0pt 842.0pt;margin:70.85pt 3.0cm 70.85pt 3.0cm;mso-header-margin:35.4pt;mso-footer-margin:35.4pt;mso-paper-source:0;}div.WordSection1{page:WordSection1;}